What the FDA labels say about taking them together
Fesoterodine and tolterodine
Fesoterodine's FDA label of April 7, 2026 names tolterodine in its contraindications section, and tolterodine's label names fesoterodine too. The fesoterodine label: “… and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine.”
Check it at the source: the fesoterodine FDA label on DailyMed (effective April 7, 2026, Pfizer Laboratories Div Pfizer Inc); the tolterodine FDA label on DailyMed (effective February 9, 2026, Torrent Pharmaceuticals Limited).
What does the fesoterodine label say about tolterodine?
Fesoterodine label, contraindicationsCONTRAINDICATIONS Toviaz is contraindicated in patients with any of the following: • known or suspected hypersensitivity to Toviaz or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology (12.1) ].
Fesoterodine label, drug interactionsIn a study in adults, coadministration of the strong CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum concentration (C max ) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine.
Source: FDA drug label (Toviaz), Pfizer Laboratories Div Pfizer Inc, effective April 7, 2026 (SPL set 5be745f0-8ae7-4c3c-9962-37d6263326f1), via openFDA; the full label on DailyMed
What does the tolterodine label say about fesoterodine?
Tolterodine label, contraindicationsTolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine. ( 4 ) Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.
Detrol label (Viatris Specialty LLC, February 15, 2023), contraindicationsDETROL is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like DETROL, are metabolized to 5-hydroxymethyl tolterodine.
Source: FDA drug label (Detrol, NDA020771), Viatris Specialty LLC, effective February 15, 2023 (SPL set 41eb00d2-64e3-4ec9-8732-4bfc81b04180), via openFDA
Source: FDA drug label (TOLTERODINE TARTRATE), Torrent Pharmaceuticals Limited, effective February 9, 2026 (SPL set db6e0b6d-0ce5-41d7-881f-881c11f530a4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fesoterodine | Tolterodine | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.794 per tablet 4 mg tablet | $0.268 per capsule 2 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once